Monika Graeser
Breast Centre, Marien-Hospital Witten Germany · Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach · Westdeutsche Studiengruppe GmbH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Monika Graeser as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:25 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCWomen's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer · principal investigator
- Ph3NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerWomen's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer · principal investigator
- Ph3NCT06081244 · NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Women's Cancer Study Group GmbH · recruiting · Triple Negative Breast Cancer · principal investigator
- N/ANCT05792150 · PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSWomen's Cancer Study Group GmbH · recruiting · Female Breast Cancer · study director
- Ph2NCT05704829 · NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerWomen's Cancer Study Group GmbH · recruiting · HER2-positive Early Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:25 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 79 citationsRCR 4.2
- 37 citationsRCR 2.7
- 35 citationsRCR 2.4
- Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.J Immunother Cancer · 202125 citationsRCR 1.3
- Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.Breast Cancer Res · 202222 citationsRCR 1.6
- 17 citationsRCR 1.1
- Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.Clin Cancer Res · 202312 citationsRCR 0.9
- Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.Lancet Oncol · 20259 citationsRCR 1.4
- Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open · 20257 citationsRCR 1.4
- 6 citationsRCR 1.2